Partner Search Form
Date 6.03.
2007
Deadline 2008 03
08
CONTACT
Organisation
University of Medicine and
Pharmacy “Victor Babes”
Timisoara
Prof. Dr. Andrei Anghel
Department Biochemistry
Email
biochim@umft.ro
Postcode
Eftimie Murgu no.2, Timisoara,
Romania
300041
Fax
+40-256-221554
City
Timisoara
Telephone
+40-723-603233
Country
Romania
Website
http://www.umft.ro/
Contact person
Address
Male/female Male
Are you familiar with the European Framework Programme?
YES
NO
PROJECT
Oncogenic pathways signatures in breast cancers as
a guide to clinical outcome and targeted therapies
Project type
Status
Large Collaborative
Project
planned for
submission
Network of
Excellence
Small
Collaborative Project
Other:
running EU project
Call references
FP 7 Health – 2007 - A Collaborative
Priorities’ Main
Research Areas
2.4 Translational research in other major
diseases
2.4.1. Cancer
Workprogramme
Topic
HEALTH-2007-2.4.1-2:Translating clinical ’omics’-technology (genomics,
proteomics, metabolomics) into innovative cancer biomarkers aiding in early
diagnosis, prognosis and treatment selection of cancer patients
HEALTH-2007-2.4.1-3:Genomic instability and genomic alterations in precancerous lesions and/or cancer
HEALTH-2007-2.4.1-6:Understanding and fighting metastasis
HEALTH-2007-2.4.1-7:Improving targeted drug delivery to cancer cells for
cancer therapeutics other than gene therapy
Project description
Our expertise is concentrated to identify patterns of pathways deregulation in
breast cancers, correlated with clinically relevant associations, disease outcomes
and targeted therapies. The expertise includes:
- detection of mutations, microsatellites and polymorphisms of hormone receptors
(estrogens, progesterone, androgen) genes with a focus on analyse and link
SNPs of the estrogens receptors (ER) gene, especially those SNPs that, at the
protein level are located in the essential functional domains (transactivating and
ligand binding domains), to the deregulation of the cell signaling pathways, the
effect on disease outcome and response to adjuvant therapy.
- expression of hormone receptors genes, HER2/neu and other breast cancer
Partner Search Form
Keywords
Partners already
involved
Project budget (for
the running
projects)
molecular markers with particular emphasis on pharmacogenomics studies.
The technical experience of our team, acquired by participation in eight previous
research projects between 2000 – 2007 coverts molecular biology approaches
like: polimerase-chain reaction (PCR), reverse transcriptase-PCR (RT-PCR),
real-time RT-PCR, DNA-sequencing, DNA cloning, gene therapy, analysis of
allele and haplotype frequencies), microscopy, immunohistochemistry, enzymelinked immuno sorbent assays (ELISA), computational chemistry, biochemistry
assays.
breast cancer
cancer biomarkers
metastasis
prognosis
genomic alterations
gene expression
immunohistochemistry
pharmacogenomics
cell signalling pathways
targeted therapeutics
Budget reserved for
SMEs
Partner Search Form
Profile of Partner sought
Role
Country /region
Start of partnership
Expertise required
technology development
research
training
dissemination
demonstration
other:
mid-term
end-phase
EU countries
start-up phase
Our team is interested in joining to a consortium for a collaborative project
regarding the molecular mechanism of cancer and translating the knowledge
created by genomics and proteomics basic research into clinical applications;
development of new cancer biomarkers, novel targeted cancer therapeutics,
understanding and fighting metastasis, genomic alterations, patterns of
oncogenic deregulation correlated with clinically relevant associations.